Metastat Inc (MTST) Financial Statements (2024 and earlier)
Company Profile
Business Address |
27 DRYDOCK AVE., 2ND FLOOR BOSTON, MA 02210 |
State of Incorp. | NV |
Fiscal Year End | February 28 |
Industry (SIC) | 2834 - Pharmaceutical Preparations (benchmarking) |
More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)Annual | Quarterly
2/28/2018 Q4 | 11/30/2017 Q3 | 8/31/2017 Q2 | 5/31/2017 Q1 | 2/28/2017 Q4 | 11/30/2016 Q3 | 8/31/2016 Q2 | |||
---|---|---|---|---|---|---|---|---|---|
ASSETS | |||||||||
Current Assets | |||||||||
Cash, cash equivalents, and short-term investments | 782 | 1,734 | 152 | 783 | 1,850 | 86 | |||
Cash and cash equivalents | 782 | 1,734 | 152 | 783 | 1,850 | 86 | |||
Receivables | 23 | ||||||||
Prepaid expense | 72 | 41 | 41 | 21 | 52 | 104 | |||
Deferred costs | |||||||||
Total current assets: | 853 | 1,775 | 216 | 804 | 1,902 | 190 | |||
Noncurrent Assets | |||||||||
Property, plant and equipment | 377 | 399 | 392 | 415 | 428 | 450 | |||
Other undisclosed noncurrent assets | 44 | 44 | 44 | 44 | 44 | 44 | |||
Total noncurrent assets: | 421 | 442 | 436 | 458 | 471 | 493 | |||
TOTAL ASSETS: | 1,274 | 2,217 | 652 | 1,262 | 2,373 | 683 | |||
LIABILITIES AND EQUITY | |||||||||
Liabilities | |||||||||
Current Liabilities | |||||||||
Accounts payable and accrued liabilities | 785 | 749 | 936 | 768 | 1,040 | 1,563 | |||
Interest and dividends payable | 17 | 16 | 16 | 16 | 8 | 49 | |||
Accounts payable | 423 | 532 | 669 | 572 | 814 | 1,241 | |||
Accrued liabilities | 345 | 201 | 252 | 180 | 219 | 274 | |||
Debt | 1,000 | 998 | 994 | 989 | 827 | 1,793 | |||
Other undisclosed current liabilities | 119 | 271 | 106 | 193 | 500 | 108 | |||
Total current liabilities: | 1,904 | 2,019 | 2,036 | 1,950 | 2,367 | 3,464 | |||
Noncurrent Liabilities | |||||||||
Liabilities, other than long-term debt, including: | 49 | 96 | 145 | 2,107 | 3,696 | 227 | |||
Derivative instruments and hedges, liabilities | 84 | 96 | 145 | 2,107 | 3,696 | 227 | |||
Other undisclosed liabilities, other than long-term debt | (35) | ||||||||
Other undisclosed noncurrent liabilities | 84 | ||||||||
Total noncurrent liabilities: | 133 | 96 | 145 | 2,107 | 3,696 | 227 | |||
Total liabilities: | 2,037 | 2,115 | 2,181 | 4,057 | 6,063 | 3,691 | |||
Equity | |||||||||
Equity, attributable to parent, including: | (762) | 102 | (1,530) | (2,795) | (3,690) | (3,007) | |||
Common stock | 1 | 1 | 0 | 0 | 0 | 0 | |||
Additional paid in capital | 27,765 | 27,459 | 25,065 | 23,523 | 23,172 | 22,469 | |||
Accumulated deficit | (28,528) | (27,358) | (26,595) | (26,319) | (26,863) | (25,477) | |||
Other undisclosed equity, attributable to parent | 0 | 0 | 0 | 0 | 0 | 0 | |||
Total equity: | (762) | 102 | (1,530) | (2,795) | (3,690) | (3,007) | |||
TOTAL LIABILITIES AND EQUITY: | 1,274 | 2,217 | 652 | 1,262 | 2,373 | 683 |
Income Statement (P&L) ($ in thousands)Annual | Quarterly
2/28/2018 Q4 | 11/30/2017 Q3 | 8/31/2017 Q2 | 5/31/2017 Q1 | 2/28/2017 Q4 | 11/30/2016 Q3 | 8/31/2016 Q2 | ||
---|---|---|---|---|---|---|---|---|
Revenues | 23 | |||||||
Gross profit: | 23 | |||||||
Operating expenses | (1,153) | (783) | (760) | (831) | (718) | (972) | ||
Other operating income (expense), net (Other Expenses) | 20 | 461 | 1,375 | (668) | 93 | |||
Other undisclosed operating income | ||||||||
Operating income (loss): | (1,153) | (763) | (276) | 544 | (1,387) | (880) | ||
Nonoperating expense (Other Nonoperating expense) | (17) | |||||||
Interest and debt expense | (30) | (30) | (30) | (2,625) | 1,249 | (402) | ||
Loss from continuing operations: | (1,200) | (793) | (306) | (2,080) | (138) | (1,281) | ||
Loss before gain (loss) on sale of properties: | (1,200) | (793) | (306) | (2,080) | (138) | (1,281) | ||
Other undisclosed net income (loss) | 30 | 30 | 30 | 2,625 | (1,249) | 402 | ||
Net income (loss) attributable to parent: | (1,170) | (763) | (276) | 544 | (1,387) | (880) | ||
Other undisclosed net loss available to common stockholders, basic | (25) | (56) | (23) | (31) | (2,361) | (103) | ||
Net income (loss) available to common stockholders, diluted: | (1,195) | (819) | (300) | 514 | (3,747) | (982) |
Comprehensive Income ($ in thousands)Annual | Quarterly
2/28/2018 Q4 | 11/30/2017 Q3 | 8/31/2017 Q2 | 5/31/2017 Q1 | 2/28/2017 Q4 | 11/30/2016 Q3 | 8/31/2016 Q2 | ||
---|---|---|---|---|---|---|---|---|
Net income (loss): | (1,170) | (763) | (276) | 544 | (1,387) | (880) | ||
Comprehensive income (loss), net of tax, attributable to parent: | (1,170) | (763) | (276) | 544 | (1,387) | (880) |
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.